EMA validates Chiesi and Protalix’s dose variation for Fabry disease
The EMA has validated Chiesi Global Rare Diseases and Protalix’s submission to update the dosing regimen of pegunigalsidase alfa.
The EMA has validated Chiesi Global Rare Diseases and Protalix’s submission to update the dosing regimen of pegunigalsidase alfa.
What's Your Reaction?
